HNSBF logo

Hansa Biopharma AB (publ) (HNSBF)

For informational purposes only. Not financial advice. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.

Hansa Biopharma AB (publ) (HNSBF) with AI Score 63/100 (Hold). Hansa Biopharma AB (publ) is a Swedish biopharmaceutical company focused on developing immunomodulatory treatments for transplants, rare IgG-mediated autoimmune conditions, gene therapy, and cancer. Market cap: 0, Sector: Healthcare.

Last analyzed: Mar 17, 2026
Hansa Biopharma AB (publ) is a Swedish biopharmaceutical company focused on developing immunomodulatory treatments for transplants, rare IgG-mediated autoimmune conditions, gene therapy, and cancer. Their lead drug candidate, Imlifidase, is in Phase 3 clinical trials for sensitized kidney transplantations patients and other indications.
63/100 AI Score

Hansa Biopharma AB (publ) (HNSBF) Healthcare & Pipeline Overview

CEORenee Aguiar-Lucander
Employees138
HeadquartersLund, SE
IPO Year2015

Hansa Biopharma AB (publ) leverages its proprietary enzyme technology platform to develop innovative immunomodulatory treatments, primarily focusing on enabling transplants and addressing rare IgG-mediated autoimmune conditions, positioning them as a key player in the biotechnology sector with a focus on novel enzyme-based therapies.

Data Provenance | Financial Data Quantitative Analysis NASDAQ Analysis: Mar 17, 2026

Investment Thesis

Hansa Biopharma presents a compelling investment thesis based on its innovative enzyme technology platform and promising drug pipeline. The company's lead drug candidate, Imlifidase, has the potential to revolutionize kidney transplantation by enabling transplants in sensitized patients. Positive Phase 3 clinical trial results and regulatory approvals could drive significant revenue growth. The company's focus on rare IgG-mediated autoimmune conditions also offers substantial market opportunities. However, the company's negative profit margin of -238.1% and reliance on clinical trial success pose significant risks. Investors should closely monitor clinical trial outcomes, regulatory decisions, and the company's ability to secure partnerships and funding.

Based on FMP financials and quantitative analysis

Key Highlights

  • Market capitalization of $0.25 billion indicates the company's current valuation in the biotechnology market.
  • Gross margin of 62.4% reflects the profitability of Hansa Biopharma's products and services.
  • Negative P/E ratio of -5.97 suggests the company is currently not profitable, typical for biotechnology companies in the development phase.
  • Profit margin of -238.1% highlights the significant investments in research and development and clinical trials.
  • Beta of 1.79 indicates higher volatility compared to the market, which is common for biotechnology stocks.

Competitors & Peers

Strengths

  • Proprietary enzyme technology platform
  • Promising clinical trial results for Imlifidase
  • Focus on unmet medical needs in niche markets
  • Experienced management team

Weaknesses

  • Negative profit margin
  • Reliance on clinical trial success
  • Limited commercial infrastructure
  • High R&D expenses

Catalysts

  • Upcoming: Phase 3 clinical trial results for Imlifidase in sensitized kidney transplantations patients.
  • Upcoming: Regulatory approval decisions for Imlifidase in Europe and the United States.
  • Ongoing: Progress in the development of NiceR platform.
  • Ongoing: Advancement of EnzE program.
  • Ongoing: Strategic collaborations and partnerships with other pharmaceutical and biotechnology companies.

Risks

  • Potential: Failure to obtain regulatory approvals for Imlifidase.
  • Potential: Competition from other biotechnology companies.
  • Potential: Patent disputes.
  • Ongoing: High R&D expenses.
  • Ongoing: Negative profit margin.

Growth Opportunities

  • Expansion of Imlifidase into new indications: Hansa Biopharma has the opportunity to expand the use of Imlifidase beyond sensitized kidney transplantations patients. The company is currently conducting Phase 2 clinical trials for antibody-mediated kidney transplant rejection and Guillain Barré syndrome. Positive results in these trials could open up new markets and drive revenue growth. The market for autoimmune disease treatments is estimated to reach $150 billion by 2028, presenting a significant opportunity for Hansa Biopharma.
  • Development of NiceR platform: Hansa Biopharma's Novel immunoglobulin cleaving enzymes for Repeat dosing (NiceR) platform has the potential to address a wide range of autoimmune diseases, transplantation, and oncology indications. The company is currently in preclinical development with NiceR. Successful development and commercialization of NiceR-based therapies could generate substantial revenue streams. The global market for enzyme therapies is projected to reach $12 billion by 2027.
  • Advancement of EnzE program: Hansa Biopharma's Enzyme based antibody Enhancement (EnzE) program focuses on cancer immunotherapy. The company is currently in preclinical development with EnzE. Successful development and commercialization of EnzE-based therapies could significantly enhance the company's presence in the oncology market. The global cancer immunotherapy market is expected to reach $175 billion by 2028.
  • Strategic collaborations and partnerships: Hansa Biopharma can pursue strategic collaborations and partnerships with other pharmaceutical and biotechnology companies to accelerate the development and commercialization of its products. The company already has a preclinical research collaboration agreement with argenx BV. Additional partnerships could provide access to new technologies, markets, and funding. The value of pharmaceutical collaborations is estimated to be $50 billion annually.
  • Geographic expansion: Hansa Biopharma can expand its geographic reach by seeking regulatory approvals and commercializing its products in new markets. The company is currently focused on Europe and the United States. Expanding into Asia and other regions could drive revenue growth. The global pharmaceutical market is expected to reach $1.5 trillion by 2025, with significant growth potential in emerging markets.

Opportunities

  • Expansion of Imlifidase into new indications
  • Development of NiceR platform
  • Advancement of EnzE program
  • Strategic collaborations and partnerships

Threats

  • Competition from other biotechnology companies
  • Regulatory hurdles
  • Patent disputes
  • Economic downturn

Competitive Advantages

  • Proprietary enzyme technology platform.
  • Strong intellectual property protection.
  • Clinical data supporting the efficacy and safety of Imlifidase.
  • Focus on unmet medical needs in niche markets.

About HNSBF

Hansa Biopharma AB (publ) is a Swedish biopharmaceutical company founded in 2007 and headquartered in Lund, Sweden. The company is dedicated to developing innovative immunomodulatory treatments using its proprietary enzyme technology platform. Hansa Biopharma's primary focus is on addressing unmet medical needs in the areas of transplantation, rare immunoglobulin G (IgG)-mediated autoimmune conditions, gene therapy, and cancer. Their lead drug candidate, Imlifidase, is an antibody cleaving enzyme therapy currently in Phase 3 clinical trials for sensitized kidney transplant patients and anti-GBM antibody disease. Imlifidase is also in Phase 2 clinical trials for antibody-mediated kidney transplant rejection and Guillain Barré syndrome. Beyond Imlifidase, Hansa Biopharma is developing Novel immunoglobulin cleaving enzymes for Repeat dosing (NiceR) for the treatment of autoimmune diseases, transplantation, and oncology. They are also working on Enzyme based antibody Enhancement (EnzE), which is a cancer immunotherapy. The company has a preclinical research collaboration agreement with argenx BV to evaluate the therapeutic potential of combining the two companies' IgG-modulating technologies, further expanding their research and development efforts.

What They Do

  • Develop immunomodulatory treatments for transplants.
  • Create therapies for rare immunoglobulin G (IgG)-mediated autoimmune conditions.
  • Develop gene therapy solutions.
  • Create cancer treatments using enzyme technology.
  • Focus on antibody cleaving enzyme therapy.
  • Develop Novel immunoglobulin cleaving enzymes for Repeat dosing (NiceR).
  • Develop Enzyme based antibody Enhancement (EnzE) for cancer immunotherapy.

Business Model

  • Develop and commercialize enzyme-based therapies.
  • Generate revenue through product sales and licensing agreements.
  • Collaborate with other pharmaceutical and biotechnology companies.
  • Focus on unmet medical needs in transplantation, autoimmune diseases, and cancer.

Industry Context

Hansa Biopharma operates within the biotechnology industry, a sector characterized by high growth potential and significant investment in research and development. The industry is driven by innovation in areas such as immunomodulatory treatments, gene therapy, and cancer immunotherapy. The competitive landscape includes companies like CMVLF (CytomX Therapeutics, Inc.), FGHQF (Fate Therapeutics Inc), GNFTF (Genfit SA), MAYNF (Madrigal Pharmaceuticals Inc), and OPORF (Opexa Therapeutics Inc.), each pursuing novel therapeutic approaches. Hansa Biopharma's focus on enzyme technology and its lead drug candidate, Imlifidase, position it as a key player in the transplantation and autoimmune disease segments.

Key Customers

  • Patients with sensitized kidney transplantations.
  • Patients with anti-GBM antibody disease.
  • Patients with antibody-mediated kidney transplant rejection.
  • Patients with Guillain Barré syndrome.
AI Confidence: 71% Updated: Mar 17, 2026

Financials

Chart & Info

Hansa Biopharma AB (publ) (HNSBF) stock price: Price data unavailable

Latest News

Analyst Consensus

Consensus Rating

Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for HNSBF.

Price Targets

Wall Street price target analysis for HNSBF.

MoonshotScore

63/100

What does this score mean?

The MoonshotScore rates HNSBF's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.

Classification

Sector Healthcare Industry Biotechnology

Latest News

Leadership: Renee Aguiar-Lucander

CEO

Renee Aguiar-Lucander is the Chief Executive Officer of Hansa Biopharma. Her background includes extensive experience in the pharmaceutical and biotechnology industries. She has held various leadership positions in companies focused on drug development and commercialization. Aguiar-Lucander has a strong track record of driving growth and innovation in the healthcare sector. Her expertise spans strategic planning, business development, and operational management. She is responsible for leading Hansa Biopharma's overall strategy and execution.

Track Record: Under Renee Aguiar-Lucander's leadership, Hansa Biopharma has made significant progress in the development of Imlifidase and other pipeline candidates. She has overseen the advancement of Imlifidase through Phase 3 clinical trials and has secured key partnerships to support the company's growth. Aguiar-Lucander has also focused on building a strong team and fostering a culture of innovation within the organization.

HNSBF OTC Market Information

The OTC Other tier represents the lowest tier of the OTC market, indicating that Hansa Biopharma AB (publ) may not meet the minimum financial standards or reporting requirements of higher tiers like OTCQX or OTCQB. Companies in this tier may have limited financial disclosure and may not be subject to the same level of regulatory oversight as companies listed on major exchanges like the NYSE or NASDAQ. Investing in OTC Other stocks carries higher risks due to the potential for limited information and increased volatility. The OTC Other tier is often populated by shell companies, bankrupt entities, and companies with questionable operations.

  • OTC Tier: OTC Other
  • Disclosure Status: Unknown
Liquidity: Liquidity for HNSBF on the OTC market is likely limited, which can result in wider bid-ask spreads and greater price volatility. This means that buying or selling shares may be more difficult and could result in less favorable prices compared to stocks listed on major exchanges. Investors should be prepared for potential challenges in executing trades quickly and efficiently. The trading volume may be low, making it difficult to accumulate or liquidate large positions without significantly impacting the stock price.
OTC Risk Factors:
  • Limited financial disclosure
  • Potential for fraud or manipulation
  • Low trading volume and liquidity
  • Higher price volatility
  • Lack of regulatory oversight
Due Diligence Checklist:
  • Verify the company's financial statements and SEC filings (if available).
  • Research the company's management team and their track record.
  • Assess the company's business model and competitive landscape.
  • Evaluate the company's legal and regulatory compliance.
  • Understand the risks associated with investing in OTC stocks.
  • Consult with a financial advisor before making any investment decisions.
Legitimacy Signals:
  • Established business operations in Sweden
  • Focus on developing innovative therapies
  • Collaboration with argenx BV
  • Clinical trials underway for Imlifidase
  • Experienced CEO with a background in the pharmaceutical industry

Hansa Biopharma AB (publ) Stock: Key Questions Answered

What does Hansa Biopharma AB (publ) do?

Hansa Biopharma AB (publ) is a biopharmaceutical company focused on developing immunomodulatory treatments for enabling transplants and addressing rare immunoglobulin G (IgG)-mediated autoimmune conditions. The company's lead drug candidate, Imlifidase, is an antibody cleaving enzyme therapy that is in Phase 3 clinical trials for use in sensitized kidney transplantations patients, as well as for anti-GBM antibody disease. Hansa Biopharma leverages its proprietary enzyme technology platform to create novel therapies that aim to improve patient outcomes in areas with significant unmet medical needs.

What do analysts say about HNSBF stock?

Analyst coverage of Hansa Biopharma AB (publ) is limited due to its OTC listing and relatively small market capitalization. However, analysts generally view the company's innovative enzyme technology platform and promising drug pipeline as positive factors. Key valuation metrics include the company's market capitalization, revenue potential of Imlifidase, and the value of its pipeline assets. Growth considerations include the successful completion of clinical trials, regulatory approvals, and commercialization efforts. Investors should conduct their own due diligence and consider the risks associated with investing in a biotechnology company with limited analyst coverage.

What are the main risks for HNSBF?

Hansa Biopharma faces several key risks, including the potential failure to obtain regulatory approvals for Imlifidase, competition from other biotechnology companies, and patent disputes. The company also faces financial risks due to its high R&D expenses and negative profit margin. Clinical trial failures or delays could significantly impact the company's prospects. Additionally, the company's reliance on a limited number of products and its presence in the highly competitive biotechnology industry pose significant challenges. Investors should carefully consider these risks before investing in HNSBF.

What are the key factors to evaluate for HNSBF?

Hansa Biopharma AB (publ) (HNSBF) currently holds an AI score of 63/100, indicating moderate score. Key strength: Proprietary enzyme technology platform. Primary risk to monitor: Potential: Failure to obtain regulatory approvals for Imlifidase.. This is not financial advice.

How frequently does HNSBF data refresh on this page?

HNSBF prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.

What has driven HNSBF's recent stock price performance?

Recent price movement in Hansa Biopharma AB (publ) (HNSBF) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Proprietary enzyme technology platform. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.

Should investors consider HNSBF overvalued or undervalued right now?

Determining whether Hansa Biopharma AB (publ) (HNSBF) is overvalued or undervalued requires examining multiple metrics. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.

What research should beginners do before buying HNSBF?

Before investing in Hansa Biopharma AB (publ) (HNSBF), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources

Analysis updated AI Score refreshed daily
Data Sources & Methodology
Market data powered by Financial Modeling Prep & Yahoo Finance. AI analysis by Stock Expert AI proprietary algorithms. Technical indicators via industry-standard calculations. Last updated: .

Data provided for informational purposes only.

Analysis Notes
  • OTC market data may be less reliable than exchange-listed data.
  • Financial information is based on available public sources and may be incomplete.
Data Sources

Popular Stocks